GLP-1 Microdosing: What the First Real-World Data Shows, and What No Trial Has Tested

What people mean by microdosing

There is no agreed definition. A 2026 commentary in Expert Opinion on Pharmacotherapy describes microdosing as using 25% to 50% of the manufacturer's recommended starting dose, or stretching the interval between doses, and lists the techniques people use: counting clicks on a multidose pen that was not designed to deliver partial doses, or injecting less often.¹ Online, the word covers several different things: taking a small fixed dose for months, staying on a titration step instead of moving up, splitting a weekly dose into two or more injections, and using a GLP-1 medicine at low dose for goals it was never tested for.

These are not the same pharmacology, and the distinction matters. Splitting a dose changes the shape of the exposure but not its amount. Taking less changes the amount. Stretching the interval does both. The sections below take them in turn.

The first real-world numbers

The only sizeable data so far come from a survey presented at ISPOR 2026 in May by researchers at Evidation Health, the company that runs the online health community the respondents were drawn from.² Of 79,602 people who answered the 51-item questionnaire, 75,886 met the analysis criteria. Among the 8,486 current users of an injectable GLP-1 medicine, 15.0% said they microdosed by the survey's definition: 9.3% currently and 5.7% in the past.

Nearly half of the current microdosers (47.6%) had started that way; the rest switched after beginning on a standard regimen. Their most common reasons were managing side effects (40.8%), reducing cost (31.9%) and supporting weight maintenance (29.6%). Current microdosers were more likely than other users to get their medicine somewhere other than their own clinician, such as a telehealth service, a weight-loss clinic or a medical spa. Overall satisfaction was similar between groups, but 51.0% of current microdosers expected to stop within a year. Social media was the most common source of information about microdosing across all respondents.²

It is a conference abstract, not a peer-reviewed paper, and every figure is self-reported by members of one online community. It measures how common the practice is and why people say they do it. It cannot measure whether it works.

What the trials say about lower doses

No trial has tested microdosing as it is practised. What exists are dose-ranging trials, which assigned people to fixed lower and higher doses, and they point the same way. In a 52-week phase 2 trial of daily semaglutide in 957 adults with obesity, weight fell by 6.0% on 0.05 mg a day, 8.6% on 0.1 mg, 11.6% on 0.2 mg and 13.8% on 0.4 mg, against 2.3% on placebo; gastrointestinal side effects, mainly nausea, rose with dose.³ The lowest arm, about 0.35 mg a week in total, still did something, and did a good deal less than the higher doses.

Tirzepatide's pivotal trial tested three maintenance doses: 15.0% weight loss at 72 weeks on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo.⁴ The 2.5 mg starting dose was never tested as a maintenance dose. In retatrutide's phase 2 trial the 1 mg arm lost 8.7% at 48 weeks against 24.2% on 12 mg, and gastrointestinal events were dose-related and partly reduced by a lower starting dose.⁵

So lower doses produce smaller effects, and some side effects fall with them. What no trial has tested is the specific claim behind much microdosing: that a small dose can keep off weight already lost, or produce most of the benefit with a fraction of the drug over the long term.

What splitting, cutting and stretching do to exposure

Semaglutide's half-life is about a week and tirzepatide's about five days; semaglutide peaks one to three days after an injection and tirzepatide within 8 to 72 hours.^6,7 That long half-life smooths the weekly curve already. The table below uses the model behind our half-life visualizer, with the labels' half-lives and times to peak, to compare steady-state exposure under six regimens. Exposure is scaled so that the label's once-weekly dose averages 100; the amounts are relative, not milligrams.

Three things follow. Splitting the same weekly amount into two injections leaves the average exposure exactly where it was and narrows the swing between peak and trough, so whatever it does for side effects, it does not reduce how much drug the body sees. Halving the dose halves the average exposure; the swing is unchanged. Stretching the interval to 10 or 14 days lowers the average and deepens the trough before each injection. It is a model: it assumes the label's average pharmacokinetics apply to every person and every dose, which no trial has checked at doses this low.

What the labels already allow

The labels have their own answer to side effects, and it is slower, not smaller. Wegovy's says that if a patient does not tolerate a dose during escalation, the next step can be delayed by four weeks.⁸ Zepbound's lists three maintenance doses, 5 mg, 10 mg and 15 mg, tells prescribers to weigh response and tolerability in choosing one, and says a lower maintenance dose can be considered if a higher one is not tolerated.⁹ Both routes keep a person on a dose that was tested. Our titration planner lays out each label's steps.

On cost, both manufacturers now sell direct to cash-paying patients at prices that depend on dose; the transition planner lists them with the date they were read.

Where the harm has actually been documented

The best-documented risk is not the low dose itself but measuring it. Pens are built to deliver set doses; counting clicks to get a fraction is off-label use of the device, and the commentary lists dosing accuracy and nonstandard measurement among its main safety concerns.¹ Compounded vials add a second problem. FDA has received reports of people giving themselves several times the intended dose of compounded semaglutide, often because the dose was written in units or millilitres and read as milligrams, or the other way round.¹⁰ Our guide to insulin syringe units and the reconstitution calculator show how a unit becomes a dose.

The contents are a third. When researchers bought semaglutide from online sellers without a prescription, the vials held 29% to 39% more than their labels said and every one contained bacterial endotoxin.¹¹ A small, carefully measured dose of the wrong amount of drug is not a small dose. And the labels list their warnings, from pancreatitis and gallbladder disease to aspiration during anaesthesia, for the drug, not for particular doses.^8,9

Retatrutide microdosing

Retatrutide is not approved anywhere; it is in phase 3 trials. Any retatrutide sold for microdosing is a grey-market product whose contents nobody has checked on the buyer's behalf, and the only human data on low doses are the phase 2 trial's 1 mg arm described above.⁵ Our retatrutide hub tracks the trials and the filing timeline, and its encyclopedia entry carries the evidence.

If you are considering it

Take the question to whoever prescribes the medicine, and bring the reason. If it is side effects, ask about delaying escalation or, for tirzepatide, a lower maintenance dose, both of which the labels provide for. If it is cost, ask about the manufacturers' cash prices and whether a lower tested dose would cost less. If it is maintenance after weight loss, the honest answer is that no trial has tested a reduced dose for that purpose; the trials that stopped the drug entirely found most of the weight came back within a year.^12,13 Our comparison of semaglutide and tirzepatide covers those trials, and the encyclopedia entries for semaglutide and tirzepatide carry the rest of the evidence.

Frequently asked questions

How common is GLP-1 microdosing?

In a 2026 survey of members of one online health community, 15% of 8,486 people using an injectable GLP-1 medicine said they microdosed, 9.3% currently and 5.7% in the past. It is self-reported and not yet a peer-reviewed paper.

Does microdosing a GLP-1 work?

No trial has tested it. Dose-ranging trials show lower doses produce smaller weight loss: daily semaglutide at 0.05 mg lost 6.0% over a year against 13.8% at 0.4 mg.

Does splitting a weekly dose reduce side effects?

Splitting keeps the total exposure the same and narrows the peak, which may matter for some people, but no trial has tested split dosing of weekly GLP-1 medicines.

Is microdosing safer?

Some side effects fall with dose, but the labels list their serious warnings for the drug, not for particular doses, and measuring small doses by pen clicks or syringe units is where FDA has documented overdoses.

What can I do instead if the side effects are too much?

The labels allow a slower escalation (Wegovy: delay the next step by four weeks) and, for tirzepatide, a lower maintenance dose. Ask the prescriber.

Related on Grey Peptides

• Semaglutide vs tirzepatide
• Half-life visualizer
• GLP-1 titration planner
• Semaglutide encyclopedia entry
• Tirzepatide encyclopedia entry
• Retatrutide hub

Sources

1. Beck, H. and Clements, J. N. (2026). Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opinion on Pharmacotherapy. Published online September 25, 2026. PMID: 42788826 · doi:10.1080/14656566.2026.2740393
2. Ramirez, E., Lee, W.-N. and Jones, S. (2026). Emerging Patterns of GLP-1 Microdosing in a Large Real-World Population. Poster PCR123, ISPOR 2026, Philadelphia, May 2026; Value in Health, 29(S6). Abstract read on ispor.org September 30, 2026. ISPOR
3. O'Neil, P. M. et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 392(10148), 637-649. PMID: 30122305 · doi:10.1016/S0140-6736(18)31773-2
4. Jastreboff, A. M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. PMID: 35658024 · doi:10.1056/NEJMoa2206038
5. Jastreboff, A. M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. PMID: 37366315 · doi:10.1056/NEJMoa2301972
6. Novo Nordisk. OZEMPIC (semaglutide) injection, US prescribing information, section 12.3: maximum concentration 1 to 3 days post dose; elimination half-life approximately 1 week. DailyMed version of June 10, 2026, read September 30, 2026.
7. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, US prescribing information, section 12.3: time to maximum concentration 8 to 72 hours; elimination half-life approximately 5 days. DailyMed version of September 2, 2026, read September 30, 2026.
8. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, US prescribing information: start 0.25 mg weekly, escalate every 4 weeks; usual maintenance 2.4 mg; if a dose is not tolerated during escalation, consider delaying escalation for 4 weeks; warnings. DailyMed version of June 30, 2026, read September 30, 2026.
9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, US prescribing information: maintenance 5 mg, 10 mg or 15 mg weekly; consider response and tolerability; consider a lower maintenance dosage if one is not tolerated; warnings. DailyMed version of September 2, 2026, read September 30, 2026.
10. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024). Read September 30, 2026. FDA
11. Ashraf, A. R. et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, 26, e65440. PMID: 39509151 · doi:10.2196/65440
12. Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. PMID: 35441470 · doi:10.1111/dom.14725
13. Aronne, L. J. et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. PMID: 38078870 · doi:10.1001/jama.2023.24945

This article describes survey data, trials and labels. It is not medical advice, and nothing here recommends any dose. Changing a dose of a prescription medicine is a decision to make with the prescriber.